| Creative arts therapy in the United States school system: An integrative systematic review of empirically evaluated interventions from the past decade JS Frydman, S Hyman, S Caputo Psychology in the Schools 59 (3), 535-556, 2022 | 9 | 2022 |
| Multi-institutional analysis of the clinical and genomic characteristics of black patients with metastatic hormone-sensitive prostate cancer MN Freeman, A Jang, J Zhu, F Sanati, L Nandagopal, D Ravindranathan, ... The Oncologist 27 (3), 220-227, 2022 | 6 | 2022 |
| Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate‐resistant prostate cancer post‐abiraterone and/or enzalutamide A Jang, SM Lanka, M Huang, CV Casado, SA Caputo, PL Sweeney, ... The Prostate 83 (11), 1028-1034, 2023 | 4 | 2023 |
| Unusual case of missed penile metastases on 68Ga-PSMA PET/CT SA Caputo, G Blair, M Hawkins, K Harris, O Sartor Clinical Nuclear Medicine 48 (8), 710-711, 2023 | 3 | 2023 |
| Prostate-Specific Membrane Antigen PET Positivity in a Lung Mass: Diagnosis of Diffuse Large B-Cell Lymphoma SA Caputo, A Jang, J Talbert, NS Saba, O Sartor Clinical Nuclear Medicine 48 (2), 190-191, 2023 | 2 | 2023 |
| Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer SA Caputo, M Hawkins, EB Jaeger, W Fleming, C Casado, C Manogue, ... The Prostate 83 (9), 879-885, 2023 | 1 | 2023 |
| Analysis of TP53 gain of function mutations in metastatic castration-resistant prostate cancer. PL Sweeney, SM Lanka, A Jang, K Gupta, S Caputo, C Casado, M Huang, ... Journal of Clinical Oncology 41 (6_suppl), 246-246, 2023 | 1 | 2023 |
| MP12-02 prospective evaluation of circulating tumor DNA (ctDNA) in detecting early progression on immune checkpoint inhibitors in patients with advanced genitourinary cancers A Jang, E Jaeger, G Rauterkus, A Liberman, I Sussman, M Light, ... The Journal of Urology 207 (Supplement 5), e165, 2022 | 1 | 2022 |
| Multi-institutional evaluation of the clinical outcomes and genomic correlates of African Americans with metastatic castration-sensitive prostate cancer (mCSPC). MMI Freeman, E Jaeger, J Zhu, A Phone, R Nussenzveig, S Caputo, ... Journal of Clinical Oncology 39 (6_suppl), 17-17, 2021 | 1 | 2021 |
| Epigenomic analysis of plasma cell-free DNA identifies stemness features associated with worse prognosis in AR-altered lethal metastatic castration resistant prostate cancer PS Chauhan, I Alahi, S Sinha, R Mueller, AL Shiang, J Webster, HX Dang, ... Cancer Research 84 (6_Supplement), 983-983, 2024 | | 2024 |
| 22. Cell-free DNA genomic and epigenomic analysis to predict survival in mCRPC patients treated with AR-directed therapy P Chauhan, I Alahi, A Shiang, J Webster, H Dang, L Greiner, B Yang, ... Cancer Genetics 278, 7, 2023 | | 2023 |
| (161) Xiaflex Nonresponders Show Alteration in Penile Measurements: Post-Market Analysis of Predictors for Treatment Success S Caputo, G Blair, G Hampel, J Greenberg, B Herzog, T Nguyen, ... The Journal of Sexual Medicine 20 (Supplement_1), qdad060. 156, 2023 | | 2023 |
| Combinatorial genomic and epigenomic cell-free DNA analysis of high-risk metastatic castration resistant prostate cancer reveals prognostic liquid biopsy signatures I Alahi, PS Chauhan, AL Shiang, J Webster, HX Dang, L Greiner, B yang, ... Cancer Research 83 (7_Supplement), 6698-6698, 2023 | | 2023 |
| Evaluation of ctDNA in patients with CRPC with pathogenic germline mutations in BRCA2. M Huang, EB Jaeger, S Caputo, C Casado, A Jang, PL Sweeney, ... Journal of Clinical Oncology 41 (6_suppl), 253-253, 2023 | | 2023 |
| Evaluation of ctDNA in patients treated with lutetium-177-PSMA-617. SM Lanka, A Jang, PL Sweeney, K Gupta, S Caputo, C Casado, M Huang, ... Journal of Clinical Oncology 41 (6_suppl), 243-243, 2023 | | 2023 |
| Comparison of ctDNA between African American and Caucasian patients with CRPC post abiraterone and/or enzalutamide. A Jang, M Huang, C Casado, S Caputo, PL Sweeney, SM Lanka, K Gupta, ... Journal of Clinical Oncology 41 (6_suppl), 35-35, 2023 | | 2023 |
| Genomic alterations in patients with prostate cancer with liver metastases. C Casado, S Caputo, EB Jaeger, A Jang, PL Sweeney, SM Lanka, ... Journal of Clinical Oncology 41 (6_suppl), 248-248, 2023 | | 2023 |
| Characterization of ctDNA findings at the end of life in patients with prostate cancer. K Gupta, S Caputo, C Casado, A Jang, PL Sweeney, SM Lanka, O Pocha, ... Journal of Clinical Oncology 41 (6_suppl), 230-230, 2023 | | 2023 |
| Genomic and epigenomic analysis of plasma cell-free DNA identifies stemness features associated with worse survival in AR-altered lethal prostate cancer PS Chauhan, I Alahi, S Sinha, AL Shiang, R Mueller, J Webster, HX Dang, ... medRxiv, 2023.12. 01.23299215, 2023 | | 2023 |
| 65. AR/enhancer alterations in metastatic castrate-resistant prostate cancer patient plasma predicts worse overall survival P Chauhan, A Shiang, H Dang, J Webster, E Ledet, R Babbra, W Feng, ... Cancer Genetics 268, 21, 2022 | | 2022 |
